Cargando…

Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma

Angiosarcoma is a vascular malignancy associated with a poor prognosis and chemotherapy resistance. The tumor immune microenvironment of angiosarcoma has not been characterized. We investigated the expression of programmed death-ligand 1 (PD-L1) and programmed death 1 (PD-1) in angiosarcoma and corr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagaria, Sanjay P., Gatalica, Zoran, Maney, Todd, Serie, Daniel, Parasramka, Mansi, Attia, Steven, Krishna, Murli, Joseph, Richard W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874284/ https://www.ncbi.nlm.nih.gov/pubmed/29623256 http://dx.doi.org/10.3389/fonc.2018.00071

Ejemplares similares

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
por: Botti, Gerardo, et al.
Publicado: (2017)

Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
por: Joneja, Upasana, et al.
Publicado: (2017)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
por: Maughan, Benjamin L., et al.
Publicado: (2017)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Primary angiosarcoma of the testis with retroperitoneal metastasis
por: Piotrowski, Joshua T., et al.
Publicado: (2018)

Adrenal Angiosarcoma: A Diagnostic Dilemma
por: Antao, Nirav, et al.
Publicado: (2019)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor
por: Brar, Rondeep, et al.
Publicado: (2009)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
por: Liao, Haotian, et al.
Publicado: (2019)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction
por: Gabriel, Emmanuel, et al.
Publicado: (2018)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
por: Mudassar, Faiqa, et al.
Publicado: (2022)

Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma
por: Kawamura, Ai, et al.
Publicado: (2019)

Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Primary perirenal angiosarcoma: A preoperative diagnostic challenge
por: Matsumura, Soichi, et al.
Publicado: (2020)

Muscle-invasive angiosarcoma of the urinary bladder: Case report
por: Madiraju, Srigita, et al.
Publicado: (2023)

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials
por: Li, Zaishang, et al.
Publicado: (2021)

The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
por: Xiao, Wen-jun, et al.
Publicado: (2019)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma
por: Golijanin, Borivoj, et al.
Publicado: (2021)

Angiosarcoma of the Adrenal Gland Treated Using a Multimodal Approach
por: Fuletra, Jay G., et al.
Publicado: (2016)

Primary adrenal angiosarcoma: A case report and review of the literature
por: Naeem, Zunaira, et al.
Publicado: (2023)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
por: Shao, Weifang, et al.
Publicado: (2022)

Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis
por: Collette, Kaylyn R., et al.
Publicado: (2022)

Synergistic Effect of Garcinol and Curcumin on Antiproliferative and Apoptotic Activity in Pancreatic Cancer Cells
por: Parasramka, Mansi A., et al.
Publicado: (2012)

Erratum to “Synergistic Effect of Garcinol and Curcumin on Antiproliferative and Apoptotic Activity in Pancreatic Cancer Cells”
por: Parasramka, Mansi A., et al.
Publicado: (2019)

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients
por: Liu, Xiaofeng, et al.
Publicado: (2019)

Angiosarcoma of the Colon Presenting with Chronic Diarrhea, Rectal Bleeding, and Pelvic Discomfort
por: Jehangir, Asad, et al.
Publicado: (2017)

Angiosarcoma of the Bladder: Review of the Literature and Discussion About a Clinical Case
por: Gerbaud, Florian, et al.
Publicado: (2017)

Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
por: Ren, Biyong, et al.
Publicado: (2021)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

Primary hepatic angiosarcoma with noncirrhotic portal hypertension: A case report
por: Wu, Xuwei, et al.
Publicado: (2023)

Angiosarcoma of the breast with hypofibrinogenemia: A rare case report and review of the literature
por: An, Ran, et al.
Publicado: (2022)

Human intravital microscopy in the study of sarcomas: an early trial of feasibility
por: Gabriel, Emmanuel M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_23hps0aqif8ed3c6k18ceihabr